TD Cowen Increases GoodRx (NASDAQ:GDRX) Price Target to $16.00

GoodRx (NASDAQ:GDRX - Free Report) had its target price hoisted by TD Cowen from $14.00 to $16.00 in a report issued on Thursday morning, Benzinga reports. TD Cowen currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. Royal Bank of Canada boosted their target price on shares of GoodRx from $7.00 to $8.00 and gave the stock a sector perform rating in a research report on Friday, March 1st. Raymond James upgraded shares of GoodRx from a market perform rating to an outperform rating and set a $10.00 target price on the stock in a research note on Thursday. SVB Leerink assumed coverage on GoodRx in a report on Monday, February 26th. They issued an outperform rating and a $8.00 price objective for the company. Leerink Partnrs restated an outperform rating on shares of GoodRx in a research note on Monday, February 26th. Finally, Truist Financial boosted their target price on GoodRx from $7.50 to $8.00 and gave the stock a hold rating in a research report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $8.95.

GoodRx Trading Up 10.9 %

Shares of GDRX traded up $0.79 during trading hours on Thursday, hitting $8.06. 4,988,219 shares of the stock were exchanged, compared to its average volume of 1,550,838. The company has a debt-to-equity ratio of 1.02, a current ratio of 6.29 and a quick ratio of 6.29. The firm has a market capitalization of $3.18 billion, a P/E ratio of -810.00, a price-to-earnings-growth ratio of 2.73 and a beta of 1.37. The business has a 50-day moving average of $6.95 and a 200-day moving average of $6.43. GoodRx has a fifty-two week low of $4.14 and a fifty-two week high of $9.37.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its earnings results on Thursday, February 29th. The company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. The business had revenue of $196.64 million during the quarter, compared to analysts' expectations of $195.59 million. GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. On average, research analysts expect that GoodRx will post 0.23 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Stifel Financial Corp boosted its stake in shares of GoodRx by 0.8% during the 3rd quarter. Stifel Financial Corp now owns 346,797 shares of the company's stock valued at $1,952,000 after purchasing an additional 2,920 shares in the last quarter. US Bancorp DE raised its position in shares of GoodRx by 3.7% in the 1st quarter. US Bancorp DE now owns 109,818 shares of the company's stock worth $780,000 after acquiring an additional 3,877 shares in the last quarter. Swiss National Bank lifted its stake in shares of GoodRx by 3.9% in the 1st quarter. Swiss National Bank now owns 155,000 shares of the company's stock valued at $1,100,000 after purchasing an additional 5,800 shares during the period. Citigroup Inc. boosted its position in shares of GoodRx by 301.7% during the third quarter. Citigroup Inc. now owns 7,997 shares of the company's stock valued at $45,000 after purchasing an additional 6,006 shares in the last quarter. Finally, WINTON GROUP Ltd lifted its position in GoodRx by 21.7% during the third quarter. WINTON GROUP Ltd now owns 37,812 shares of the company's stock valued at $213,000 after buying an additional 6,732 shares during the period. 63.77% of the stock is owned by hedge funds and other institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.